Albert Bourla
Summary
Albert Bourla is Pfizer’s Chairman of the Board and Chief Executive Officer, a role he has held since January 2019 after more than 25 years in senior positions at the company. ([pfizer.com](https://www.pfizer.com/people/leadership/board-of-directors/dr-albert_bourla))
Biography
Bourla joined Pfizer in 1993 and held leadership roles in animal health, established products, vaccines, oncology, consumer healthcare, and Pfizer’s Innovative Health business. He became Chief Operating Officer in January 2018 and succeeded Ian Read as CEO in January 2019. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/albert_bourla_elected_to_pfizer_s_board_of_directors?utm_source=openai)) He earned a Doctor of Veterinary Medicine degree and a Ph.D. in the Biotechnology of Reproduction from Aristotle University in Greece. As CEO, he has emphasized Pfizer’s shift toward a science-focused portfolio, greater research and development investment, and growth in oncology, vaccines, and other specialty medicines. He has also overseen Pfizer’s work with BioNTech on its COVID-19 vaccine and the development of Paxlovid, the company’s oral COVID-19 treatment. ([pfizer.com](https://www.pfizer.com/people/leadership/board-of-directors/dr-albert_bourla))
Notable achievements
- Led Pfizer during the rapid development and rollout of its BioNTech-partnered COVID-19 vaccine and Paxlovid. ([pfizer.com](https://www.pfizer.com/people/leadership/board-of-directors/dr-albert_bourla))
- Oversaw the company’s 2023 acquisition of Seagen, a major oncology-focused transaction. ([pfizer.com](https://www.pfizer.com/people/leadership/board-of-directors/dr-albert_bourla))
- Advanced Pfizer’s move toward a science-driven portfolio by divesting some non-core businesses and increasing emphasis on research and technology. ([pfizer.com](https://www.pfizer.com/people/leadership/board-of-directors/dr-albert_bourla))
- Earlier in his career, helped lead businesses that expanded Pfizer’s oncology and vaccine operations before becoming CEO. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer_names_albert_bourla_chief_operating_officer?utm_source=openai))
- In 2025, Pfizer reported four key U.S. approvals and treatment or vaccine reach of more than 448 million patients under his leadership. ([sec.gov](https://www.sec.gov/Archives/edgar/data/78003/000007800326000033/pfe-20260312.htm))
Problem areas / controversies
- Pfizer sharply reduced its revenue outlook in 2023 as demand for COVID-19 products fell, followed by a multibillion-dollar cost-cutting program and workforce reductions. ([investing.com](https://www.investing.com/news/stock-market-news/pfizer-considers-cost-cuts-as-demand-for-covid-products-falls-3140298?utm_source=openai))
- Activist investor Starboard Value took an approximately $1 billion stake in Pfizer in 2024 and criticized the company’s performance, research productivity, and acquisition decisions, putting pressure on Bourla’s leadership. ([investing.com](https://www.investing.com/news/economy-news/pfizer-raises-profit-forecast-after-beating-thirdquarter-estimates-3687898?utm_source=openai))
- The post-pandemic revenue decline and the need to replace large COVID-era sales have left Pfizer facing questions about the pace and effectiveness of its broader product and business-development strategy. ([apnews.com](https://apnews.com/article/df0d9790b33201f957493b6e50155635?utm_source=openai))